In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Nurix Therapeutics Inc (NASDAQ: NRIX) closed at $13.98 down -1.27% from its previous closing price of $14.16. In other words, the price has decreased by -$1.27 from its previous closing price. On the day, 0.48 million shares were traded. NRIX stock price reached its highest trading level at $14.31 during the session, while it also had its lowest trading level at $13.56.
Ratios:
For a deeper understanding of Nurix Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.13.
On March 09, 2023, Barclays started tracking the stock assigning a Overweight rating and target price of $20.
On February 28, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $25.Oppenheimer initiated its Outperform rating on February 28, 2023, with a $25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 02 ’24 when van Houte Hans sold 3,499 shares for $12.83 per share. The transaction valued at 44,878 led to the insider holds 68,333 shares of the business.
Hansen Gwenn sold 2,007 shares of NRIX for $24,169 on Apr 30 ’24. The Chief Scientific Officer now owns 39,601 shares after completing the transaction at $12.04 per share. On Apr 30 ’24, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 1,513 shares for $12.04 each. As a result, the insider received 18,220 and left with 19,838 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 853723648 and an Enterprise Value of 481138240. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.25 while its Price-to-Book (P/B) ratio in mrq is 4.07. Its current Enterprise Value per Revenue stands at 5.948 whereas that against EBITDA is -3.188.
Stock Price History:
The Beta on a monthly basis for NRIX is 2.12, which has changed by 0.3841642 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, NRIX has reached a high of $18.12, while it has fallen to a 52-week low of $4.22. The 50-Day Moving Average of the stock is 0.67%, while the 200-Day Moving Average is calculated to be 46.67%.
Shares Statistics:
For the past three months, NRIX has traded an average of 1.07M shares per day and 886060 over the past ten days. A total of 59.32M shares are outstanding, with a floating share count of 54.62M. Insiders hold about 7.92% of the company’s shares, while institutions hold 69.61% stake in the company. Shares short for NRIX as of 1713139200 were 7036201 with a Short Ratio of 6.59, compared to 1710460800 on 6408056. Therefore, it implies a Short% of Shares Outstanding of 7036201 and a Short% of Float of 15.870000000000001.
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.67 for the current quarter, with a high estimate of -$0.47 and a low estimate of -$0.89, while EPS last year was -$0.45. The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.64 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$2.44 and -$3.53 for the fiscal current year, implying an average EPS of -$2.91. EPS for the following year is -$3.17, with 10.0 analysts recommending between -$2.44 and -$4.93.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $17.88M. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $13.5M.
A total of 8 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $89.08M, while the lowest revenue estimate was $57.09M, resulting in an average revenue estimate of $74.24M. In the same quarter a year ago, actual revenue was $76.99MBased on 8 analysts’ estimates, the company’s revenue will be $67.69M in the next fiscal year. The high estimate is $90M and the low estimate is $33.35M.
